AZD9291
2016-09-058
Phase 2 small_molecule active
Quick answer
AZD9291 for Non-Small Cell Lung Cancer With EGFR T790M Mutation is a Phase 2 program (small_molecule) at Samsung Bioepis NL B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Samsung Bioepis NL B.V.
- Indication
- Non-Small Cell Lung Cancer With EGFR T790M Mutation
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active